

TABLE OF CONTENTS

October 19, 2009

No. 2160

BUSINESS

- 1 Takeda Introduces "Mutual Consent System" for Decision Making
- 2 Kowa Licenses Livalo to Algorithm in the Middle East, North Africa
- 3 Sanwa Kagaku Licenses FYX-051 from Fuji Yakuhin
- 3 Meiji Seika Aims at Top-3 Position in CNS
- 4 Daiichi Sankyo to Make Vaccines One of Its Core Businesses
- 4 New Drugs Account for 13% of Total Sales: Novartis
- 5 **Sales Force Effectiveness Summit Japan 2009**
 - Effective Cooperation with Wholesalers Essential: Mr Takada
 - Cost-Effectiveness Should Be Evaluated: Mr Paterson
 - NBI Does Not Teach MRs in Their Education: Mr Hayakawa
 - Ajinomoto to Train Consulting MRs: Mr Shinji
 - Effectiveness of E-detailing Difficult to Assess: Mr Takema
- 6 **BUSINESS NEWS IN BRIEF**
 - Schering-Plough Launches Double-Dose Nasonex
 - Ranbaxy Starts Marketing Daiichi Sankyo's Products in Mexico
 - BioWa Licenses POTELLIGENT Technology to Otsuka
 - Kureha, MTPC, Daiichi Sankyo Restructure Domestic Marketing System for Kremezin
 - Alfresa Ties Up with Tampei Nakata
- 7 **ON THE MOVE**
 - Hans-Dieter Hausner to Be Appointed President of Bayer Holding

REGULATORY

- 8 Discussions of Medical Fees Halted
- 8 Industry Should Show Evidence of Pressure on Profits due to Drug Price Curtailment: JMARI
- 9 Budget to Support Development of Unapproved Drugs, Indications Cut to ¥10 Bil.
 - No Effects Expected on Discussions on NHI Price Maintenance System Proposed by FPMAJ: Mr Kinoshita
 - Decision Is Regrettable: JPMA
- 9 *Koroshō's* Supplementary Budget Cut by ¥435.9 Bil.
- 10 *Koroshō* to Reshuffle CDFS's 1st, 2nd Committees on Drugs Next April
- 10 Additional Safety Information to Be Provided on Obescare
 - Additional Explanations Required on Two Points
- 11 **REGULATORY NEWS IN BRIEF**
 - Astellas to Apply for IBS in Women as Addn'l Indication for Irribow
 - Multaq Recommended for Approval in the EU: sanofi-aventis

R&D

- 12 **BioJapan 2009**
 - Merck to License More Compounds in Early Stage: Dr Wiederrecht

- J&J Interested in Products in PIII or on the Market: Mr LaPolla
- 12 Mylan to Develop Cysteamine, Zeria Oral Phosphate
- 13 Disappointment Prevails at JPMA Seminar on Development of Unapproved Drugs
- 13 *Koroshō* to Continue to Support Development of Unapproved Drugs via Non-budgetary Measures
- 14 No More Problems with Speed or Quality of Clinical Trials in Japan: *Koroshō's* WG
 - Payment Method Needs to Be Improved
- 14 **R&D NEWS IN BRIEF**
 - Sosei Transfers Assets Related to AD923 to Pharmasol
 - Oncolys' NRTI Patented in US
 - Regorafenib Stabilizes RCC in 81% of Patients: Bayer Schering
 - New Treatment Regimen of Taxol More Effective Than Standard Regimen: JGOG
 - Nexavar in Combination with Xeloda Improves PFS: Bayer, Onyx
 - Switching Tamoxifen to Aromasin Shows Significant DFS Benefits: Pfizer

GENERICS

- 16 Sandoz's Somatropin Equivalent to Original Product: Mr Nakamichi
- 16 JSGM to Propose Standard Prescription Ordering Form
- 16 Certification of Pharmacists Specializing in Generics As Well
- 17 Pharmacists Should Play Key Role in Promoting Use of Generics: JSGM Seminar
 - Prescription Form Needs Further Change: Prof. Muto
- 17 *Koroshō* Urges Nat'l Univ. Hospitals to Use More Generics
 - Pharmacists Should Play Greater Role Selecting Drugs
- 18 2012 IGPA Annual Conference to Be Held in Japan

MEDICAL DEVICES

- 20 **MEDICAL DEVICE NEWS IN BRIEF**
 - HSTTC Licenses Tumor Markers to TransGenic
 - Terumo Applies for Left Ventricular Assist System
- 20 **TOPICS**
 - Astellas Adopts Work-at-Home Scheme
 - Banyu Starts Work-at-Home Scheme for Employees from October

MEDICAL FACILITIES & NURSING CARE

- 22 Erbitux's Efficacy Correlated with KRAS Gene Mutation in Japanese Patients as Well
- 22 GSK, Novartis Contract with *Koroshō* to Supply Flu Vaccines
- 22 Some Healthcare Professionals Don't Recommend Use of Relief System to Their Patients to Save Time
- 23 **TOPICS**
 - JPMA to Stress Value of New Drugs on TV